On this page
Read the experiment
The finding and its boundary
The investigators reported reduced glaucoma-like findings in treated animals. The surgically created outflow model does not establish human glaucoma treatment or safe eye drops.
Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma.
- Experiment
- Experimental animal investigation with the intervention and outcomes specified in the indexed abstract.
- Study system
- Rats with three episcleral veins cauterized
- Measured outcome
- Eye pressure, vascular presentation and ocular tissue across six weeks
- Reported result
- The investigators reported reduced glaucoma-like findings in treated animals.
- What this cannot establish
- The surgically created outflow model does not establish human glaucoma treatment or safe eye drops.
What was actually tested
Rats with three episcleral veins cauterized. The investigators measured eye pressure, vascular presentation and ocular tissue across six weeks. The investigators reported reduced glaucoma-like findings in treated animals.
The detail that changes the takeaway
The study uses a defined obstruction to raise pressure. That is a more specific question than whether an investigational peptide is good for the eyes. Visual function, pressure control and optic-nerve preservation need their own measurements, and no retail preparation is validated by the animal route alone.
How far the result travels
The surgically created outflow model does not establish human glaucoma treatment or safe eye drops.
Keep the eye condition explicit
The corneal-incision experiment concerns a wound at the eye surface, whereas this investigation raises pressure through episcleral cauterization. They should be compared as different injuries, not pooled into a general eye-health benefit. The essential BPC-157 guide explains the difference between biological interest and an established clinical use.
References & product documents
The evidence and service information used here.